Foscarnet Decreases HIV-1 Plasma Load

Abstract

We observed decreased HIV-1 plasma load in all patients treated with foscarnet, regardless of presence or absence of clinical or biologic CMV infection. This decrease supports the proposition that foscarnet anti-HIV-1 activity may be of clinical importance.

Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection

“…12 The amino acid change T700A within the DNA polymerase, associated with CMV resistance to FOS, 13,14 was identified in two different blood samples. Of note, this mutation was not detected in a blood sample obtained during the previous CMV infection, 8 months earlier (Fig. 1).…”

“…Among AIDS patients receiving FOS treatment for CMV disease, several studies have reported an inhibitory effect on plasma HIV load. 7,8 Furthermore, FOS represents a therapeutic option for patients infected with late-stage HIV infection and multidrug-resistance. The efficiency of this molecule used as salvage therapy has been recently underlined by several studies, with a markedly decrease of plasma HIV load and an improvement of immunological status.…”

Fungemia Due toSaccharomycesSpecies in a Patient Treated with EnteralSaccharomyces boulardii

“…A lumbar puncture performed 2 weeks later showed studies about the effects of this antiviral agent on HIV replication a detectable HIV RNA viral load at 3 log 10 copies/mL. A third in vivo were published [3,4]. Both investigators observed signifiepisode of mental dysfunction, associated with an important rise cant reductions of HIV plasma viral loads in patients who were in CSF viral load (5.1 log 10 RNA HIV copies/mL), occurred 6 treated with foscarnet.…”

“…ceftazidime and ciprofloxacin because of a nosocomial pulmonary infection. On day 34, the temperature was elevated to 39ЊC and M. charomyces species from an affected bowel (e.g., ischemic or in- (e.g., patients with AIDS and patients receiving corticosteroid therSaccharomyces fungemia in AIDS patients after treatment for chronic apy) [3][4][5][6][7][8]. In all reported cases, therapy has consisted of support- …”

Effectiveness of rescue antiretroviral therapy including intravenously administered zidovudine and foscarnet in a child with HIV-1 enteropathy

“…The rationale for intravenous administration of antiretroviral agents was the concern that oral drugs could be poorly absorbed because of the enteropathy. Foscarnet, a pyrophosphate analogue, inhibits the reverse transcriptase of HIV-1 and has been shown to decrease HIV-1 replication in vitro [3,4] and in vivo in adults [1,2]. However, its use in clinical practice is limited by a lack of oral bioavailability and nephrotoxicity.…”